About four years after litigation began, Moderna has reached a settlement to resolve patent claims related to the lipid nanoparticle (LNP) technology used in its mRNA-based COVID-19 vaccine, Spikevax. The case was initiated in February 2022 by Genevant, a subsidiary of Roivant, and Arbutus Biopharma, which alleged that Moderna infringed six patents covering LNP delivery systems.
Under the agreement, Moderna will pay $950 million upfront in July 2026. The company could owe an additional $1.3 billion depending on the outcome of an appeal concerning its potential liability for vaccine sales made under certain government contracts. In total, the settlement could amount to $2.25 billion. Moderna stated that it does not expect to record a charge for the contingent payment because it does not consider that outcome probable.
The lawsuit, filed in federal court in Delaware, followed unsuccessful efforts by Moderna to invalidate two Arbutus patents. Genevant and Arbutus sought damages in the form of a reasonable royalty on infringing sales but did not seek to block the manufacture or distribution of Moderna’s vaccines. The dispute later expanded to include Moderna’s respiratory syncytial virus vaccine, mRESVIA, which received U.S. Food and Drug Administration approval in 2024.
The settlement was finalized shortly before a jury trial was scheduled to begin. In resolving the dispute, Genevant and Arbutus have granted Moderna a global non-exclusive license to their LNP technology for infectious disease applications and agreed not to pursue further litigation over certain related patents and products. In exchange, Moderna has agreed not to challenge the validity of specific Genevant and Arbutus patents. The companies said the agreement resolves all global LNP-related litigation between them.
Moderna continues to appeal a recent decision rejecting its contractor defense, which argued that it should be shielded from certain patent claims under government-contractor immunity statutes. A Delaware district judge ruled that such statutory protections apply when infringement benefits the government directly, rather than the public at large. The appeal is pending before the U.S. Court of Appeals for the Federal Circuit.
Following the settlement announcement, Moderna said it expects to hold between $4.5 billion and $5 billion in cash and cash equivalents at the end of 2026. Bernstein analyst Courtney Breen noted that if the additional $1.3 billion payment becomes necessary, the company’s cash reserves could fall to approximately $3.2 billion by that time.
In a statement, Moderna CEO Stéphane Bancel said, “Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna’s exciting near-term future.” He added that the company anticipates returning to revenue growth in 2026 and ending the year with more than $5 billion in liquidity, while working toward breakeven in 2028.
Analysts described the financial terms as lower than some investors had anticipated. William Blair said the outcome was better than feared, noting that some market expectations had approached $5 billion in potential liability. Shares of Moderna rose in Wednesday trading following the announcement.
Separately, Moderna remains engaged in other legal matters, including patent disputes involving Pfizer and BioNTech related to mRNA technology.
Impact on Moderna’s Future Pipeline
The settlement enables Moderna to avoid ongoing royalty payments on the disputed LNP technology and removes a major legal overhang for the company.
The patent dispute dates back several years and centers on lipid nanoparticle (LNP) delivery systems used in mRNA-based medicines. These microscopic lipid carriers protect fragile genetic material and help deliver it into human cells, allowing the body to produce proteins that trigger an immune response. The companies that brought the case argued that their patented technology was used without a proper licensing agreement.
During the rapid development of COVID-19 vaccines, LNP delivery systems became one of the most important technological components enabling mRNA therapies to function effectively. As a result, intellectual property related to these delivery platforms became the subject of multiple legal challenges across the biotechnology industry.
Role of Lipid Nanoparticle Technology
Lipid nanoparticles are considered one of the most significant breakthroughs in modern drug delivery. They protect mRNA molecules from degradation and help them cross cell membranes safely. Without this system, many mRNA therapies would not be able to reach their target cells.
Researchers have spent decades refining this technology, and several biotech companies hold patents related to its formulation and manufacturing process. The dispute highlighted the commercial value of these innovations, especially as mRNA platforms are increasingly used in vaccines, rare disease treatments, and cancer therapies.
